Who is sponsoring NCT00068042?

NCT00068042 is sponsored by Pfizer.

What condition does NCT00068042 study?

NCT00068042 studies Acromegaly.

What drugs are being tested in NCT00068042?

Interventions: Pegvisomant, Sandostatin LAR.

What is the status of NCT00068042?

NCT00068042 is currently COMPLETED.

Last reviewed 2008-04-03 · How we verify

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

NCT00068042 Phase 4 COMPLETED

The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Details

Lead sponsor	Pfizer
Phase	Phase 4
Status	COMPLETED
Enrolment	100
Start date	2003-04
Completion	2006-05

Conditions

Acromegaly

Interventions

Pegvisomant
Sandostatin LAR

Primary outcomes

Percentage of patients with normal IGF-1 concentration at Final Visit (Week 52)

Countries

United States, Australia, Brazil, Canada, France, Germany, Greece, Ireland, Italy, Norway, Spain, Sweden, United Kingdom